

Mometamax Ultra™

**One Dose. Healthy Ears¹.
Happy Dog.**



About Canine Otitis Externa ^{2,3}

- Usually acute
- Inflammation alters the ear canal environment
- Resident bacteria and fungi multiply
- Can affect one ear or both ears to a similar or varying extent

Common signs

- Rubbing or scratching ears
- Head shaking
- Pain or discomfort
- Unpleasant odour or discharge

Otitis Externa Prevalence by the Numbers


- Affects up to **1 in 7** dogs seen in general practice^{4,5}




- **1 in 4** dogs with otitis externa will experience at least 1 recurrence⁴

- **80%** of cases involve two or more organisms⁶

- Mixed infections of *Staphylococcus pseudintermedius* and *Malassezia pachydermatis* in more than two-thirds of cases^{7,8}



Staphylococcus pseudintermedius



Malassezia pachydermatis

Introducing a Novel Approach to Treating Canine Otitis Externa

3 IN 1



Packaging is for demonstration purposes only and does not reflect the actual packaging registered in every market.


Convenient Single-Dose Treatment

MOMETAMAX ULTRA™ is a Novel combination of 3 proven and effective ingredients

- Gentamicin is a broad-spectrum bactericidal antibiotic
- Posaconazole is a broad-spectrum antifungal
- Mometasone furoate is a high potency topical corticosteroid with few systemic side effects

Reliable Improvement in Clinical Signs¹

- Peak concentration was reached soon after application followed by clinical improvement.
- In dogs with otitis externa associated with a mixed culture of *Staphylococcus pseudintermedius* and *Malassezia pachydermatis*⁹:
 - **100% HAD HEALTHIER EARS** by 2 weeks after treatment: ear scores of 4/12 or less
 - **100% HAD HEALTHY EARS** by 4 weeks after treatment: ear scores of 3/12 or less*
 - **73% MICROBIOLOGICAL CURE** of *S. pseudintermedius* by 4 weeks
 - **81% MICROBIOLOGICAL CURE** of *M. pachydermatis* by 4 weeks



Healthier ears had a clinical score of less than 4/12

Healthy ears had a clinical score of less than 3/12

*It may take up to 6 weeks for maximum clinical response

[†]Reduction of veterinary clinical ear scores in a masked randomised multicenter field trial in client-owned dogs with otitis externa in Germany, France and the Netherlands.

[‡]Drug concentrations measured in ear wax ($\mu\text{g/g}$) in healthy dogs

Gentamicin

Broad-spectrum bactericidal antibiotic

- Rapidly kills susceptible Gram-positive and Gram-negative bacteria, including *Staphylococcus pseudintermedius*¹⁰
- Low levels of resistance found in isolates from cases of canine otitis externa¹¹
- Is categorised to support prudent and responsible use of antimicrobials - No other ear product contains an antimicrobial in a lower AMEG class, with many having antimicrobials from higher categories¹³

Posaconazole

High potency antifungal for canine otitis externa

- Rapidly kills susceptible fungi, including *Malassezia pachydermatis*¹⁰
- More potent antifungal than many other ingredients for canine otitis externa^{9,12}

40-100x MORE POTENT

against *M. pachydermatis* *in vitro* than clotrimazole, miconazole, nystatin and terbinafine^{9,11}



Mometasone Furoate

High potency topical corticosteroid with few systemic side effects

- A leading corticosteroid for otitis externa with a 10-year+ history
- Reduces inflammation and resolves clinical signs (eg, redness, swelling, ulceration and discharge)




Well-Tolerated in safety studies of Dogs⁹




SINGLE DOSE

A single dose of Mometamax Ultra was effective, well-tolerated with safety demonstrated in client-owned dogs with acute otitis externa or acute flare-ups of recurrent otitis externa¹.



FEW LOCAL EFFECTS

Reversible, minimal to mild atrophy of the epidermis of external ear canal or epithelial lining of tympanum in dogs administered the recommended treatment dose three times at 2-week intervals¹.



NO ADVERSE EVENTS FOUND IN CLINICAL TRIALS

No treatment-related adverse reactions were observed in clinical trials.



FEW SYSTEMIC EVENTS

Baseline and ACTH-stimulated cortisol concentrations in dogs administered the recommended treatment dose three times at 2-week intervals were not significantly different from placebo-treated dogs.

Cortisol increased in all groups (1x, 3x and 5x) in response to ACTH stimulation after cessation of treatment indicating sufficient adrenal function as well as reversible effects even at higher doses.

MOMETAMAX ULTRA: A Novel, Single-Dose Treatment You Can Now Consider For:

Innovation

- ✓ Single-dose treatment
- ✓ Unique combination of 3 active ingredients
- ✓ Convenience with efficacy and safety demonstrated in studies¹

Improving compliance

- ✓ For veterinary professional use only
- ✓ No administration struggles at home
- ✓ Correct dosage ensured

Increasing certainty

- ✓ 1 in-clinic administration
- ✓ Simple dosing
- ✓ Provides up to 4-6 weeks of efficacy

Mometamax Ultra™

A Single-Dose, In-Clinic Treatment

- Ensuring full-dose administration
- A unique combination of three proven active ingredients, in a preservative-free formulation presented in a multi-dose bottle
- Clinical response lasting up to 4-6 weeks
- Convenient, effective and well-tolerated in safety studies

Contact your MSD Animal Health representative about how a single-dose, in-clinic administration of MOMETAMAX ULTRA can benefit your patients, your clients, and your practice.



One Dose. Healthy Ears¹. Happy Dog.

MOMETAMAX ULTRA™ ear drops, suspension for dogs.

For animal treatment only.

Use medicines responsibly.

Legal categories: ROI [POM], NI [POM-V]

Composition: Each dose (0.8 ml) contains: Gentamicin sulfate equivalent to 6880 IU gentamicin, Posaconazole 2.08 mg, Mometasone furoate monohydrate equivalent to 1.68 mg mometasone furoate.

Indications: Treatment of acute otitis externa or acute exacerbation of recurrent otitis externa caused by mixed bacterial and fungal infections with *Staphylococcus pseudintermedius* susceptible to gentamicin and *Malassezia pachydermatis* susceptible to posaconazole.

Contraindications: Do not use in cases of hypersensitivity to the active substances or to any of the excipients, to corticosteroids, to other azole antifungal agents and to other aminoglycosides. Do not use if the eardrum is perforated. Do not use in pregnant or breeding animals. Do not use concurrently with substances known to cause ototoxicity. Do not use in dogs with generalized demodicosis.

Special precautions for use: Safety has not been established in dogs <3 months of age or weighing <3 kg. Use with precaution in dogs with suspected or confirmed endocrine disorder.

Dosing: Auricular use. Single treatment. Administration by a veterinarian practitioner or under their close supervision. The maximum clinical response may not be seen until 28 to 42 days after administration.

Adverse reactions: No adverse reactions related to treatment were observed in clinical trials.

Shelf life: Once open use within 3 months.

Special precautions for storage: None.

Presentation: Carton box containing 1 bottle, an LDPE adapter and 20 syringes.

Market authorisation holder: Intervet International B. V., Boxmeer, Netherlands.

References: **1.** L.Heuer; C. Wilhelm; O. Roy; W.Löhlein; O. Wolf; E. Zschiesche :Clinical microbiology, safety, and efficacy of a single in-clinic dose of gentamicin, posaconazole, and mometasone furoate in dogs with otitis externa; Presented at WSAVA Congress; Lisbon, Portugal; September 27–29, 2023. **2.** Kasai T, Fukui Y, Aoki K, et al. *J Appl Microbiol.* 2020;130:1084-1091. **3.** Borriello G, Paradiso R, Catozzi C, et al. *PLoS One.* 2020;15:e0241447. **4.** Perry LR, MacLennan B, Korven R, et al. *Can Vet J.* 2017;58:168-174. **5.** O'Neill DG, Church DB, McGreevy PD, et al. *PLoS One.* 2014;9:e90501. **6.** Petrov V, Zhelev G, Marutsov P, et al. *Bulg J Vet Med.* 2018;22:1-10. **7.** Lyskova P, Vydrzalova M, Mazurova J. *J Vet Med A.* 2007;54:559-563. **8.** Szewczuk MA, Zych S, Sablik P. *Slov Vet Res.* 2020;57:33-43. **9.** European Medicines Agency. Mometamax Ultra. EPAR – Product Information & Assessment Report. 2022. **10.** Paterson S. *Small Anim Pract.* 2016;57:668-678. **11.** Bourelly C, Cazeau G, Jarrige N, et al. *Epidemiol Inf.* 2019;147:1-10. **12.** Peano A, Johnson E, Chiavassa E, et al. *J Fungi.* 2020;6:93. **13.** EMA categorisation of antimicrobials - https://www.ema.europa.eu/en/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_en.pdf

For further information about side effects, precautions, warnings and contra-indications please consult the product SPC, packaging leaflets or: MSD Animal Health, Red Oak North, South County Business Park, Leopardstown, Dublin 18, Ireland. Tel: +353 (0)1 2970220.

Email: vet-support.ie@msd.com Web: www.msd-animal-health.ie

